Phathom Pharmaceuticals, Inc. PHAT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$30.37M+67.8% | -$21.15M+71.6% | -$29.97M+65.0% | -$75.81M+17.1% | -$94.32M-13.8% | ||
| $110K-37.9% | $128K-33.7% | $156K-18.3% | $172K-12.7% | $177K-17.3% | ||
| $5.53M-0.1% | $5.61M-16.1% | $9.3M+65.0% | $8.27M+35.6% | $5.54M-1.5% | ||
| $844K+21.3% | $809K+28.6% | $775K+31.6% | $734K+46.8% | $696K+46.8% | ||
| $2.6M+207% | $22.34M+25.9% | $4.53M-55.4% | $14.89M+113% | -$2.43M-208% | ||
| -$665K-105% | —— | —— | $1.85M— | $12.33M+2,863% | ||
| -$3.12M+55.1% | $27.57M+38.3% | $1.11M-90.2% | $12.38M+42.4% | -$6.96M-38.8% | ||
| $171K— | $8.86M— | -$1.39M+39.6% | -$6.25M-327% | $0+100% | ||
| -$1.61M+11.3% | -$865K+3.5% | -$1.21M+1.8% | -$1.32M-0.3% | -$1.81M-9.4% | ||
| -$829K— | —— | —— | —— | $0— | ||
| -$15.65M+81.6% | -$5M+92.1% | -$14.12M+77.8% | -$62.73M+11.3% | -$84.93M-23.1% | ||
| $61K+239% | $87K+1,640% | $27K-38.6% | $97K+111% | $18K-55.0% | ||
| -$61K-239% | -$87K-1,640% | -$27K+38.6% | -$97K-111% | -$18K+55.0% | ||
| $173.25M— | $0-100% | $0— | $0-100% | $0-100% | ||
| $229.05M— | —— | —— | —— | $0— | ||
| $591K— | $1.27M-20.9% | $293K+1,495% | $80K— | $0— | ||
| $66.64M— | -$97K-100% | -$271K-100% | $80K-99.7% | $0-100% | ||
| $50.93M+160% | -$5.19M+86.1% | -$14.41M— | -$62.75M-36.4% | -$84.95M-43.6% | ||
| $4.94M-5.5% | $5.43M+12.8% | $5.4M+15.9% | $5.31M+30.2% | $5.23M+39.7% | ||
| $3.54M-55.9% | —— | —— | —— | $8.04M-30.3% | ||
| $844K+21.3% | $809K+28.6% | $775K+31.6% | $734K+46.8% | $696K+46.8% | ||
| -$157K-271% | $68K-64.0% | $10K-89.7% | —— | $92K-42.9% | ||
| $10K-75.0% | $90K+120% | $66K+50.0% | $26K-42.2% | $40K-11.1% | ||
| -$6.92M+11.4% | —— | -$1.39M— | —— | -$7.81M-1,647% | ||
| $0-100% | —— | —— | —— | $899K— | ||
| -$1.61M+11.3% | -$865K+3.5% | -$1.21M+1.8% | -$1.32M-0.3% | -$1.81M-9.4% | ||
| -$128K— | —— | —— | —— | $0— | ||
| $121.97M— | $0— | —— | —— | $0— | ||
| $0-100% | -$51K-738% | $42K+520% | -$35K-1,267% | $44K+529% | ||
| $3.5M— | $0-100% | $0-100% | $0— | $0— | ||
| $2.07M-2.5% | —— | $3.13M+5.4% | —— | $2.13M+199% | ||
| $1.54M-17.0% | —— | $1.12M-31.6% | —— | $1.85M+141% | ||
| -$15.71M+81.5% | -$5.09M+92.0% | -$14.14M+77.8% | -$62.83M+11.2% | -$84.95M-23.0% | ||
| -$15.71M+81.5% | -$5.09M+92.0% | -$14.14M+77.8% | -$62.83M+11.2% | -$84.95M-23.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Phathom Pharmaceuticals, Inc. generate?
- Phathom Pharmaceuticals, Inc. (PHAT) generated -$97.5M in operating cash flow over the trailing twelve months.
- What is Phathom Pharmaceuticals, Inc.'s free cash flow?
- After $272.0K of capital expenditures, Phathom Pharmaceuticals, Inc.'s free cash flow was -$97.8M over the trailing twelve months, up 65.4% year over year.
- Where does Phathom Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Phathom Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
